Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-CLS-579 in advanced solid tumors
NCT04417465Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Jun 2020
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 1, open-label trial of ABBV-CLS-579 in solid tumor (advanced stage), head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC) and 2 more (6 arms), sponsored by AbbVie Inc. Primary endpoints: Maximum Observed Plasma/Serum Concentration at Day 64, Time to Maximum Concentration at Day 64 and 6 more. Started Jun 2020; status: completed.
02
Drugs
ABBV-CLS-579
03
Conditions
solid tumor (advanced stage)head and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)clear cell renal cell carcinoma (ccRCC)microsatellite instability-high cancer (MSI-H)
Beyond the preview
Go deeper on NCT04417465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04417465.